Table 2 Visual acuity changes from baseline and adjusted predictions of visual acuity by linear-mixed model.
Characteristics | Total eyes | Typical nAMD | PCV | ||||||
|---|---|---|---|---|---|---|---|---|---|
Ranibizumab | Aflibercept | p value | Ranibizumab | Aflibercept | p value | Ranibizumab | Aflibercept | p value | |
VA change from baseline (LogMAR letter), mean ± SD | |||||||||
3 months | 9.71 ± 15.79 | 8.50 ± 18.63 | 0.615* | 7.56 ± 18.69 | 5.02 ± 20.08 | 0.502* | 11.89 ± 11.93 | 12.53 ± 16.13 | 0.821* |
1 year | 6.72 ± 17.52 | 2.62 ± 24.51 | 0.182* | 1.39 ± 18.45 | − 1.74 ± 24.46 | 0.472* | 11.98 ± 14.95 | 8.00 ± 23.83 | 0.334* |
2 years | 2.05 ± 22.18 | − 0.44 ± 21.95 | 0.497* | − 8.07 ± 23.95 | − 5.77 ± 22.82 | 0.672* | 10.85 ± 16.19 | 6.00 ± 19.30 | 0.245* |
3 years | − 1.26 ± 21.48 | − 1.79 ± 24.56 | 0.905* | − 10.67 ± 23.54 | − 7.18 ± 25.14 | 0.611* | 6.58 ± 16.09 | 3.86 ± 23.18 | 0.603* |
4 years | − 2.21 ± 21.55 | − 4.95 ± 26.30 | 0.583* | − 11.37 ± 23.42 | − 11.05 ± 23.54 | 0.963* | 6.03 ± 16.01 | 1.50 ± 29.42 | 0.492* |
Adjusted VA (LogMAR letter), mean ± SD | |||||||||
3 months | 62.70 ± 2.09 | 61.00 ± 2.61 | 0.610† | 57.47 ± 3.05 | 57.17 ± 3.68 | 0.951† | 67.99 ± 2.62 | 65.48 ± 3.38 | 0.557† |
1 year | 59.60 ± 2.14 | 55.11 ± 2.65 | 0.187† | 51.39 ± 3.14 | 50.62 ± 3.72 | 0.873† | 67.87 ± 2.68 | 60.57 ± 3.46 | 0.095† |
2 years | 54.82 ± 2.28 | 52.36 ± 2.75 | 0.490† | 42.60 ± 3.41 | 45.80 ± 3.87 | 0.535† | 66.20 ± 2.79 | 60.22 ± 3.57 | 0.187† |
3 years | 49.99 ± 2.43 | 49.95 ± 3.01 | 0.992† | 37.99 ± 3.68 | 43.49 ± 4.34 | 0.334† | 61.01 ± 2.94 | 57.18 ± 3.82 | 0.427† |
4 years | 48.64 ± 2.52 | 46.80 ± 3.13 | 0.649† | 36.81 ± 3.79 | 40.20 ± 4.52 | 0.566† | 59.81 ± 3.07 | 54.21 ± 3.96 | 0.265† |